Cross-Specialty Comparison of the Managed Care Process of Biologic Agents Spotlight
Spherix’s RealTime Dynamix™ quarterly offerings span a variety of autoimmune indications, allowing for cross-specialty comparisons and launch benchmarking. The RealTime Dynamix™ series tracks every major biologic/small molecule launch, on a quarterly basis, for the first eighteen months in the market.
Each report series is offered at the indication level, including: rheumatoid arthritis, psoriatic arthritis, psoriasis, atopic dermatitis, Crohn’s disease, and ulcerative colitis. Coverage in most indications dates back to 2015, allowing for ample cross-comparison opportunities between launches.
Click here to view complimentary data highlights showcasing just a few metrics covered approximately one year post-market entry for a selected agent in each indication (from multiple reports in atopic dermatitis, IBD, psoriasis, psoriatic arthritis, and rheumatoid arthritis).
Contact [email protected] for more information about the highlighted reports or to see if your company has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.